Table 3.
Characteristics | HR (95% C.I.) | P-value |
---|---|---|
Age at first diagnosis of primary disease | 1.001 (0.985-1.018) | 0.863 |
Stage IV at initial diagnosis of primary BC | 0.843 (0.475-1.495) | 0.559 |
Site of initial distant metastases | ||
Bone | 0.695 (0.498-0.969) | 0.033 |
Lung | 1.138 (0.811-1.597) | 0.453 |
Liver | 1.431 (0.934-2.190) | 0.099 |
Subtype with trastuzumab effect | ||
HR-positive/HER2-negative | reference | |
HER2-positive withoutTrastuzumab | 1.892 (1.177-3.040) | 0.008 |
HER2-positive with Trastuzumab | 1.064 (0.650-1.741) | 0.656 |
TNBC | 1.652 (1.071-2.546) | 0.023 |